Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM2PP3_Moderate
The NM_001042432.2(CLN3):c.485C>T(p.Ser162Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000686 in 1,458,698 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
CLN3 (HGNC:2074): (CLN3 lysosomal/endosomal transmembrane protein, battenin) This gene encodes a protein that is involved in lysosomal function. Mutations in this, as well as other neuronal ceroid-lipofuscinosis (CLN) genes, cause neurodegenerative diseases commonly known as Batten disease or collectively known as neuronal ceroid lipofuscinoses (NCLs). Many alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2008]
Loss of glycosylation at S162 (P = 0.0262);Loss of glycosylation at S162 (P = 0.0262);Loss of glycosylation at S162 (P = 0.0262);Loss of glycosylation at S162 (P = 0.0262);.;.;.;Loss of glycosylation at S162 (P = 0.0262);.;Loss of glycosylation at S162 (P = 0.0262);.;.;Loss of glycosylation at S162 (P = 0.0262);.;.;.;